Details

MOLECULAR TARGETS<br> Cellular Assays in Drug Discovery<br> Gene Knockout Models<br> Reporter Gene Assay Systems for the Investigation of GPCRs<br> From the Human Genome to New Drugs: The Potential of Orphan GPCRs<br> SYNTHESIS<br> Stereoselective Synthesis with the Help of Recombinant Enzymes<br> Nucleic Acid Drugs<br> ANALYSIS<br> Recent Trends in Enantioseparation of Chiral Drugs<br> Affinity Chromatography<br> NMR-based Drug Discovery<br> 13C- and 15N-Isotopic Labeling of Proteins<br> Antibody Fragments as Crystallization Enhancers<br> KINETICS, METABOLISM AND TOXICOLOGY<br> Pharmacogenetics: The Effect of Inherited Genetic Variation on Drug Disposition and Drug Response<br> Pharmacogenomics of Bioavaliability and Elimination<br> Toxicogenomics: Integration of New Molecular Biological Tools in Toxicology<br>

"...a welcome addition to the library of anyone seeking to build a multidisciplinary group" <br> Applied Organometallic Chemistry, June 2004<br> <br> "In all, the book touches on some of the trendiest subjects that interface to form the frontier of modern medicinal chemistry."<br> <br> Kevin G. Rice, Division of Medicinal and Natural Products Chemistry, College of Pharmacy, The University of Iowa, Iowa City, Journal of Medicinal Chemistry, Vol. 47, No. 26, 2004<br> <br>

Theodor Dingermann, born 1948, studied pharmacy at the University of Erlangen, Germany. After obtaining his PhD in biochemistry, he worked as a post-doc at Yale University, New Haven. In 1987 he completed his habilitation for the disciplines of biochemistry and molecular biology. Since 1990 he is full professor of pharmaceutical biology at Goethe University in Frankfurt, Germany. He is editor-in-chief of two journals, "Die Pharmazie" and "Pharmazie in unserer Zeit". Furthermore, he is chairman of the working group on biopharmaceuticals and vice-chairman of the committee on pharmaceutical biology of the German Arzneibuch commission. From 2000 to 2004 he has been President of the German Pharmaceutical Society.<br> <br> Dieter Steinhilber, born 1959, studied pharmacy at the University of Tubingen (Germany). After an assistantship there he spent a postdoc period with Nobel prize winner Bengt Samuelsson in Stockholm (Sweden). In 1994 he received an associate professorship and since 2000 he is a full professor for pharmaceutical chemistry at the Goethe University in Frankfurt (Germany). He is also the chairman of the scientific advisory board of Phenion, a company for molecular cell physiology.<br> <br> Gerd Folkers is professor of pharmaceutical chemistry at the ETH Zurich since 1991. He studied pharmacy at the University of Bonn and earned his Ph.D. on structure-activity relationships of desapurines. He then moved to the University of Tubingen, where he completed his habilitation in pharmaceutical chemistry. During a stay with H.-D. Hoeltje in Bern, he studied new research methods in computer-aided molecular design and expanded this knowledge during other stays with T. Blundell at the Birkbeck College and E. Meyer at Texas A&M University.<br> The focus of his research is the molecular interaction between drugs and their binding sites. Besides his work on the molecular mechanism of "conventional" nucleoside therapeutics against virus infections and cancer, his special interest has shifted to immuno-therapeutics.

Molecular Biology and Genetic Engineering have made a great impact on the methods and strategies of modern pharmaceutical and medicinal chemistry, transforming virtually every step in the drug development process, from target finding to drug design and ADMET analysis. Even the synthesis and manufacture of pharmaceutically active compounds has benefited from novel approaches based on molecular biology tools.<br> <br> From the Contents:<br> * Cellular Assays in Drug Discovery<br> * Transgenic Models<br> * Reporter Gene Assay Systems<br> * Stereoselective Synthesis with Recombinant Enzymes<br> * Nucleic Acid Drugs<br> * Enantioseparation of Chiral Drugs<br> * NMR-based Drug Discovery<br> * Pharmacogenomics and Toxicogenomics<br> <br> With its broad coverage and up-to-date treatment, this volume is essential reading for all pharmaceutical chemists, molecular biologists and medical researchers using molecular biology tools to study drugs and their action.<br>

DE